New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technolog...( - Immunocytokine Combining Peregr...)

- Immunocytokine Combining Peregrine's Anti-PS Antibodies and IL-2 Protected 80% of Animals From a Lethal Challenge With a Highly Aggressive Form of Breast

Cancer -

- New Data Presented at International Conference on Vascular Targeted Therapies in Oncology Further Supports a Second Mechanism of Action for

Anti-PS Antibodies -

MANDELIEU, France and TUSTIN, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus infections, today reported that data presented at the International Conference on Vascular Targeted Therapies in Oncology showed that a fusion protein combining interleukin-2 (IL-2) and 2aG4, an anti-phosphatidylserine (anti-PS) antibody similar to Peregrine's bavituximab, was effective in stimulating a strong protective immune response when added to a cancer vaccine. The combination was effective in protecting animals against a lethal challenge with a highly aggressive form of breast cancer. The new data is being presented by Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center in Dallas and a member of the Peregrine Scientific Resource Board.

In the study reported today, breast cancer cells were irradiated to inactivate them and to expose the anti-PS target on their surface. The irradiated cancer cells were then treated with the 2aG4-IL-2 fusion protein to increase their immunogenicity before being used to vaccinate the study animals. Eighty percent of the immunized mice survived a subsequent lethal challenge with live versions of these agg
'/>"/>